Tumor News and Research RSS Feed - Tumor News and Research

Insulin signaling pathway has significant influence on the growth of glioblastomas

Insulin signaling pathway has significant influence on the growth of glioblastomas

Drugs that target insulin pathways to slow or stop the growth of brain tumors are going in the right direction but appear to be on the wrong track, according to new research at Rice University. [More]
Statistical analyses identifies higher-than-expected rates of pediatric cancers in 2 Florida areas

Statistical analyses identifies higher-than-expected rates of pediatric cancers in 2 Florida areas

Higher-than-expected rates of pediatric cancers have been identified in the Miami metro area and an area west of the Everglades in a series of five statistical analyses conducted for Science and Public Policy, an open-access, online public-policy journal published by the American Statistical Association. [More]
Adjuvant Ipilimumab improves survival after complete resection of high-risk stage III melanoma

Adjuvant Ipilimumab improves survival after complete resection of high-risk stage III melanoma

Results of an EORTC trial appearing in The Lancet Oncology show that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, but that this treatment was also associated with a high rate of immune-related adverse events. [More]
Myc cancer gene allows tumor cells to divide, provokes cell suicide process

Myc cancer gene allows tumor cells to divide, provokes cell suicide process

Myc cancer gene empowers tumor cells to relentlessly divide but simultaneously, provokes a cell suicide process called apoptosis. Myc controls cells by commanding the expression of every tenth of the genes in the nucleus of a tumor cell. However, in spite of more than two decades of intense research, no Myc motivated killer genes have been found. [More]
Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

Early data in a preliminary human study show that an experimental immune system drug is generally safe and well tolerated in women with metastatic, triple-negative breast cancer, a persistently difficult form of the disease to treat. [More]
Targeting PD-1/PD-L1 signaling may open up new therapy options for lung cancer patients

Targeting PD-1/PD-L1 signaling may open up new therapy options for lung cancer patients

New findings about regulation of PD-L1, a protein that allows cancer to evade the immune system, has shown therapeutic promise for several cancers, including the most common form of lung cancer. [More]
Two new research papers reveal how breast cancer cells avoid anoikis

Two new research papers reveal how breast cancer cells avoid anoikis

Two new papers from the lab of Zach Schafer, Coleman Assistant Professor of Cancer Biology at the University of Notre Dame, offer insights into how breast cancer cells avoid anoikis, which is cell death induced by detachment from the extracellular matrix (ECM). [More]
Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse). [More]
UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

The University of New Mexico Cancer Center recently enrolled its first patient in a phase 3 international clinical trial to test a personalized vaccine against metastatic kidney cancer. Kidney cancer has proven particularly difficult to treat with chemotherapy, and numerous attempts to create a kidney cancer vaccine have not improved survival rates. [More]
Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has submitted an application to the European Medicines Agency for Orphan Drug Designation for its drug candidate CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. [More]
PCF announces Stupski Prize in Prostate Cancer Computational Oncology

PCF announces Stupski Prize in Prostate Cancer Computational Oncology

The Prostate Cancer Foundation is pleased to announce the Stupski Prize in Prostate Cancer Computational Oncology, a first-in-field initiative designed to attract novel ideas to the rapidly changing field of large-scale cancer bioinformatics. [More]
CAP pathologist shares four tips for women with breast cancer

CAP pathologist shares four tips for women with breast cancer

For any woman, a diagnosis of breast cancer can be frightening. But as Rita Wilson's recent experience shows, engaging with the keystone of the diagnosis - the pathology report - can be critical in achieving good outcomes. Informed by rigorous scientific processes, training and team discussion, pathology reports identify a diagnosis, help indicate the right providers for a patient's care team and shape treatment plans. [More]
Research explores new, personalized ovarian cancer treatments

Research explores new, personalized ovarian cancer treatments

Identifying molecular changes that occur in tissue after chemotherapy could be crucial in advancing treatments for ovarian cancer, according to research from Magee-Womens Research Institute and Foundation and the University of Pittsburgh Cancer Institute, partner with UPMC CancerCenter, presented today at the American Association for Cancer Research Annual Meeting 2015. [More]
Pembrolizumab drug halts tumor growth in 76% of patients with pleural mesothelioma

Pembrolizumab drug halts tumor growth in 76% of patients with pleural mesothelioma

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania. [More]
Penn professor to be recognized with AACR-CRI Lloyd J. Old Award in Cancer Immunology

Penn professor to be recognized with AACR-CRI Lloyd J. Old Award in Cancer Immunology

The American Association for Cancer Research and the Cancer Research Institute will recognize Carl H. June, MD, the Richard W. Vague professor in immunotherapy at the Perelman School of Medicine and director of the Center for Cellular Immunotherapies at the University of Pennsylvania in Philadelphia, with the third annual AACR-CRI Lloyd J. Old Award in Cancer Immunology at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22. [More]
Paradigm to provide PCDx test to oncologists in TD2 networks

Paradigm to provide PCDx test to oncologists in TD2 networks

Paradigm and Translational Drug Development today announced a partnership under which Paradigm will provide their PCDx test to TD2's affiliated oncology provider networks. [More]
New book can change the way cancer is detected

New book can change the way cancer is detected

Jenny Hrbacek's new book, Cancer Free! Are You SURE? can play a role in changing the way cancer is detected. It contains lifesaving information. Far too many people – and she was one of them – get a diagnosis out of the blue and are whisked to the operating table or chemotherapy chair in a matter of days. [More]
Study points to potential therapeutic targets to halt tumor cell movement

Study points to potential therapeutic targets to halt tumor cell movement

Tumor cells become lethal when they spread. Blocking this process can be a powerful way to stop cancer. Historically, scientists thought that tumor cells migrated by brute force, actively pushing through whatever tissue was in their way, but recent evidence has shown that tumor cells may be more methodical. And in a new study, Cornell University researchers report that tumor cells take advantage of already-cleared paths to migrate unimpeded [More]
James Allison to be honored with 2015 Pezcoller Foundation-AACR International Award for Cancer Research

James Allison to be honored with 2015 Pezcoller Foundation-AACR International Award for Cancer Research

The 2015 Pezcoller Foundation-American Association for Cancer Research (AACR) International Award for Cancer Research will be presented to James P. Allison, PhD, at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22. [More]
Donald S. Coffey to receive Margaret Foti Award at AACR Annual Meeting 2015

Donald S. Coffey to receive Margaret Foti Award at AACR Annual Meeting 2015

Donald S. Coffey, PhD, will be honored with the ninth annual American Association for Cancer Research Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22. [More]
Advertisement
Advertisement